Tafasitamab Clinical Trials
20 recruitingDrug
Phase 216Phase 16Early Phase 11Phase 31
Showing 1–20 of 20 trials
Recruiting
Phase 2
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
Large B-cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute28 enrolled1 locationNCT06760156
Recruiting
Phase 2
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
Hodgkin Lymphoma
M.D. Anderson Cancer Center36 enrolled1 locationNCT05615636
Recruiting
Phase 2
Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
University of Washington30 enrolled1 locationNCT05453500
Recruiting
Phase 2
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
Lymphoma
Memorial Sloan Kettering Cancer Center27 enrolled7 locationsNCT07030699
Recruiting
Phase 2
Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder
Monomorphic B-Cell Post-Transplant Lymphoproliferative DisorderPolymorphic Post-Transplant Lymphoproliferative Disorder
Timothy Voorhees28 enrolled3 locationsNCT05786040
Recruiting
Phase 1Phase 2
Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
ALL, Childhood B-CellAcute Lymphoid Leukemia RelapseAcute Lymphocytic Leukemia Refractory
University Hospital Tuebingen20 enrolled11 locationsNCT05366218
Recruiting
Early Phase 1
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
Lymphoma, B-Cell
Canadian Cancer Trials Group18 enrolled4 locationsNCT04161248
Recruiting
Phase 1Phase 2
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
University of Washington35 enrolled1 locationNCT05455697
Recruiting
Phase 2
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Hematologic Malignancies
Incyte Corporation25 enrolled5 locationsNCT06465433
Recruiting
Phase 1Phase 2
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Systemic Lupus ErythematosusLupusAutoimmune Disorders+2 more
M.D. Anderson Cancer Center47 enrolled2 locationsNCT06434363
Recruiting
Phase 2
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRefractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsRecurrent Grade 3b Follicular Lymphoma+19 more
David Bond, MD37 enrolled1 locationNCT05821088
Recruiting
Phase 1
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia
OHSU Knight Cancer Institute27 enrolled1 locationNCT05943496
Recruiting
Phase 2
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Grade 3b Follicular Lymphoma
SWOG Cancer Research Network227 enrolled104 locationsNCT05890352
Recruiting
Phase 1Phase 2
Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Mantle Cell Lymphoma
Alvaro Alencar, MD27 enrolled1 locationNCT06029309
Recruiting
Phase 2
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
Non-Hodgkin Lymphoma
University of Cologne20 enrolled6 locationsNCT05583071
Recruiting
Phase 2
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Follicular LymphomaMarginal Zone Lymphoma
Masonic Cancer Center, University of Minnesota65 enrolled1 locationNCT06792825
Recruiting
Phase 1Phase 2
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
Primary Central Nervous System LymphomaSecondary Central Nervous System LymphomaCNS Lymphoma
James Rubenstein35 enrolled1 locationNCT05351593
Recruiting
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
Incyte Corporation100 enrolled25 locationsNCT04981795
Recruiting
Phase 2
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
Academic and Community Cancer Research United100 enrolled2 locationsNCT05910801
Recruiting
Phase 3
Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
DLBCL
Beijing InnoCare Pharma Tech Co., Ltd.244 enrolled20 locationsNCT06521255